SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is trending due to a notable sell-off after its affiliated drone entries were not selected in a government gauntlet, despite recently securing new orders for counter-drone systems from Middle East defense clients. Community discussions are sharply divided between those who view the gauntlet outcome as insignificant to Ondas' broader defense strategy, and frustrated investors who cite persistent market manipulation hindering any sustained upward movement.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Conflicting reports regarding Oracle's data center expansion with OpenAI in Texas are fueling intense community debate, with perspectives split on whether a potential cancellation benefits Oracle's debt management or signals broader challenges for its AI strategy ahead of upcoming earnings.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is captivating the market with exceptional relative strength and surging volume, hitting new 52-week highs amidst broader market downturns, as the community actively speculates on a looming short squeeze and potential buyout, affirming its undervalued cell therapy platform.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the investment community speculates that controversies surrounding a key FDA official will pave the way for accelerated approval of its Duchenne muscular dystrophy therapy, deramiocel. This comes ahead of the company's highly anticipated Phase 3 data presentation next week, fueling optimism for a potential short squeeze and significant upside.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as escalating geopolitical tensions in the Middle East, coupled with rising oil prices, fuels speculation of increased market volatility, with the community actively discussing its use as a hedge against potential broader market downturns.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is experiencing significant volatility amid widespread community outrage and strong speculation regarding the FDA's stance on its Huntington's disease gene therapy, AMT-130, with many now discussing a potential regulatory reversal or a "softball" path forward after an initial setback.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum is trending as NVIDIA's multi-billion-dollar investment to secure optical components for AI infrastructure fuels significant analyst upgrades and S&P 500 inclusion speculation. The community is sharply divided, debating LITE's soaring valuation and recent insider sales against the sector's robust demand and persistent short squeeze.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending as investor enthusiasm for defense technology and anticipated US military drone contracts drives massive trading volume and price appreciation, despite mixed community reactions regarding its performance in a recent drone competition.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is highly volatile as a clarified major data center project with AI giants boosts sentiment, while escalating geopolitical tensions and rising energy costs for global memory chip production introduce sector-wide jitters. The community is actively debating if current dips are a buying opportunity ahead of anticipated explosive earnings for Micron's in-demand AI memory, or a sign of deeper market corrections.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. It also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment offers products and services sold for applications within the data center, communication networks, and commercial and industrial markets in North America and Latin America. The Asia Pacific segment includes products and services sold for applications within the data center, communication networks, and commercial or industrial markets throughout Greater China, Australia and New Zealand, Southeast Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Columbus, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv Holdings Co (VRT) is trending as the community speculates on its imminent S&P 500 inclusion following a strong Q4 earnings report highlighting explosive demand for its AI data center cooling and power management solutions. Investors are actively debating whether its recent surge reflects sustainable AI infrastructure growth or a potential "sell the news" event.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The bank now holds about 3.88 million shares, down from 17.8 million shares in September 2025.</li><li>Recently, the FDA issued warning letters to 30 telehealth companies over the misleading marketing of compounded GLP-1 weight-loss drugs.</li><li>Hims has faced scrutiny over its $49 compounded weight-loss pill, while Novo Nordisk filed a lawsuit against the company last month.</li></ul>Shares of Hims &amp; Hers Health, Inc. rose nearly 1% in early premarket trading on Friday, even as a new regulatory filing showed JPMorgan Chase &amp; Co. sharply reduced its stake.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> fell over 3% on Thursday to end at $15.88, but rose 0.4% in extended trading. Shares of the telehealth firm are on track to snap a 13-week losing streak.<h2 class="st-heading-2">JPMorgan Cuts Stake</h2>A new regulatory filing showed that JPMorgan held about 3.88 million shares, representing 1.7% of Hims &amp; Hers’ common stock as of Feb. 27, marking a sharp drop from 17.8 million, or about 8.1%, disclosed by the bank as of September 2025.The new filing indicates JPMorgan reduced its position by roughly 14 million shares, cutting its ownership to below the 5% disclosure threshold.<h2 class="st-heading-2">FDA Scrutiny Over Weight Loss Drugs</h2>The stake reduction comes as the digital health company faces growing regulatory scrutiny tied to its weight-loss offerings. The U.S. Food and Drug Administration (FDA) recently issued&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-slips-overnight-fda-warns-telehealth-firms-glp1-claims/cZd99SIRI57">warning letters</a> to 30 telehealth companies over false or misleading marketing of compounded GLP-1 weight-loss drugs, including Semaglutide, Tirzepatide and Liraglutide, which are the active ingredients in Novo Nordisk’s Wegovy and Ozempic, and Eli Lilly’s Zepbound and Mounjaro. Hims was also included in an earlier round of warning letters issued in September.The telehealth firm has also faced scrutiny over its $49 compounded weight-loss pill, while Novo Nordisk filed a lawsuit against the company last month. CEO Andrew Dudum said on the latest earnings call that GLP-1 users who use the compound form represent only a small minority of the platform’s subscribers as the company expands into other healthcare categories.<h2 class="st-heading-2">Peptides Emerge As Potential Growth Driver</h2>The scrutiny comes even as investors focus on&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-stock-finds-glp1-hedge-rallies-rfk-jr-signals-peptide-clearances/cZdeIBHRI2w">peptides</a>, which are short chains of amino acids that regulate biological functions are being explored for uses such as muscle recovery and aging.&nbsp;Interest in the category has grown after&nbsp;U.S. Secretary of Health and Human Services&nbsp;Robert F. Kennedy Jr. said the FDA is reviewing whether some previously restricted peptides could again be produced by U.S. compounding pharmacies. The Futurum Group CEO Daniel Newman said that Hims “is the most likely public company play for peptides at scale” and said the category “could easily offset any GLP-1 related downside.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘bearish’ amid ‘extremely low’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_04ed344d27.webp" alt="hims ss.png" width="969" height="144"><figcaption>HIMS sentiment and message volume as of March 6 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/TrendAnnihilator/message/646757398">expects</a> a “most likely choppy day tomorrow.”<stembedurl>https://stocktwits.com/TrendAnnihilator/message/646757398</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/AB5HUNNID/message/646749216">speculated</a>, “JP Morgan slashed 14 million shares Feb 27th on the day that short selling was restricted. THE STOCK RALLIED. Was JPM shorting all along?”<stembedurl>https://stocktwits.com/AB5HUNNID/message/646749216</stembedurl>HIMS stock has shed over half of its value so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Hims & Hers Health logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

HIMS Stock Rises Premarket: Investors Brush Off JPMorgan Stake Cut Amid FDA GLP-1 Crackdown

The stake reduction comes as Hims navigates regulatory scrutiny over weight-loss drugs, while expanding into other healthcare categories.

Equity

Hims and Hers Expands Its Technology Driven Consumer Health Platform

HIMS expands its tech-driven care platform with data-led Labs testing, new menopause and testosterone services and global expansion into Canada.

William Blair Investment Management LLC Trims Stock Holdings in Hims & Hers Health, Inc. $HIMS

William Blair Investment Management LLC lowered its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 64.0% in the third quarter, according to the company in its most recent...

CI Investments Inc. Has $11.71 Million Position in Hims & Hers Health, Inc. $HIMS

CI Investments Inc. boosted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 6,659.7% during the third quarter, according to the company in its most recent filing with the...

<ul class="summary-bullets"><li>The FDA issued warning letters to 30 telehealth companies over allegedly misleading marketing tied to compounded GLP-1 weight-loss drugs.</li><li>Investor focus has also shifted to peptides, after Health Secretary Robert F. Kennedy Jr. said regulators are reviewing whether roughly 14 previously restricted peptides.</li><li>Retail traders largely dismissed the warning as a marketing issue, saying the dispute centers on advertising language, with some calling Hims a “deep value” stock.</li></ul>Shares of Hims &amp; Hers Health Inc. (HIMS) slipped more than 1% in overnight trading on Tuesday after the U.S. Food and Drug Administration (FDA) issued warning letters to 30 telehealth companies over false or misleading marketing claims tied to compounded GLP-1 weight-loss drugs.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> tumbled 4% to end at $15.82 on Tuesday and has shed over half of its value so far this year.<h2 class="st-heading-2">FDA Targets GLP-1 Marketing Claims</h2>The FDA said some companies promoted compounded medicines as equivalent to approved GLP-1 treatments or branded the products in ways that obscured&nbsp;their manufacturing location.The agency said the violations involved marketing claims around compounded Semaglutide, Sirzepatide and Liraglutide, the active ingredients used in Novo Nordisk’s Wegovy and Ozempic and Eli Lilly’s Zepbound and Mounjaro.“It’s a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms—and taking swift action,” FDA Commissioner Marty Makary said in a statement.The companies have 15 working days to respond and outline corrective steps. The move follows an earlier round of warning letters sent in September to companies involved in selling weight-loss drugs, including Eli Lilly, Novo Nordisk and Hims, as part of a broader crackdown on drug advertising.Hims also came under fire recently after the FDA warned it could take action over the company’s $49 compounded weight-loss pill, while Novo Nordisk escalated the dispute last month by filing a lawsuit against the company.<h2 class="st-heading-2">Retail Traders Downplay Regulatory Risk</h2>On Stocktwits, retail sentiment for HIMS was ‘bearish’ amid ‘low’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_ae53d337b0.webp" alt="hims ss.png" width="970" height="144"><figcaption>HIMS sentiment and message volume as of March 4 | Source: Stocktwits</figcaption></figure>Despite the warning letter, retail traders largely dismissed the move as a marketing issue rather than a fundamental threat to the company’s business model.Some users&nbsp;<a href="https://stocktwits.com/DadSuggests/message/646491751">noted</a> that regulators repeatedly focused on advertising and promotional claims, arguing the dispute centers on marketing language rather than the legality of compounded drugs. One trader&nbsp;<a href="https://stocktwits.com/DadSuggests/message/646511948">said</a> they were “not worried about FDA overhang.”Others&nbsp;<a href="https://stocktwits.com/BullRooster31/message/646507870">pointed</a> to the company’s potential growth in peptides and broader telehealth services, saying the firm&nbsp;<a href="https://stocktwits.com/GalacticFiskerShip/message/646491677">could</a> pivot toward brand-name GLP-1 drugs while expanding into new therapies and international markets. Users called Hims a “discount deep value stock.”<h2 class="st-heading-2">Peptides Seen As A Key Growth Driver</h2>Investor focus has increasingly shifted toward&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-stock-finds-glp1-hedge-rallies-rfk-jr-signals-peptide-clearances/cZdeIBHRI2w">peptides</a> after the U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said regulators are reviewing whether several peptides that were previously restricted could be allowed for domestic compounding again.Peptides are small chains of amino acids that influence various biological processes. Some are promoted for benefits such as muscle growth, immune support and healthy aging, though effectiveness varies across different compounds.Kennedy said roughly 14 peptides could potentially move back to a category that allows U.S. compounding pharmacies to produce them. The Futurum Group CEO Daniel Newman said Hims &amp; Hers is “the most likely public company play for peptides at scale,” adding the category could offset potential GLP-1 related downside.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Hims & Hers Health, Inc. is displayed on a smartphone screen on May 04, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Hims Stock Slips Overnight As FDA Warns Telehealth Firms Over GLP-1 Claims — Why Traders Think The ‘Overhang’ Won’t Last

The warnings involve compounded versions of Semaglutide, Tirzepatide and Liraglutide, the active ingredients in Wegovy, Ozempic and Mounjaro.

<ul class="summary-bullets"><li>Robert F. Kennedy Jr. said the FDA is reviewing restrictions on peptides, with about 14 potentially returning to a category that allows U.S. compounding in the coming weeks.</li><li>Kennedy told The Joe Rogan Experience he hopes peptides will be accessible through “ethical suppliers.”</li><li>The company said on its latest earnings call that GLP-1 users represent only a small portion of subscribers.</li></ul>Shares of Hims &amp; Hers Health, Inc. (HIMS) jumped on Monday after Robert F. Kennedy Jr. said the U.S. Food and Drug Administration (FDA) is reviewing the status of several peptides that were previously restricted, signaling a potential reopening of a fast-growing category that analysts say could benefit the digital health company.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> jumped nearly 14% on Monday, posting its best session in over four months, to end at $16.48.&nbsp;<h2 class="st-heading-2">Peptide Reclassification Review Underway</h2>Speaking on The Joe Rogan Experience, Kennedy said that nearly two dozen peptides had previously been moved to a restricted category, preventing U.S.-based compounding pharmacies from legally producing them. He said the FDA is now considering moving roughly 14 of those peptides back to a category that would allow domestic compounding.“My hope is that they’re going to get moved to a place where people have access from ethical suppliers,” Kennedy said, while acknowledging that the scientific evidence supporting some uses of the peptides “hasn’t been fully gathered.”Kennedy argued that the earlier restriction contributed to a surge in gray-market sourcing. “We created the black market,” he said, describing how patients seeking peptides turned to unregulated suppliers once legal compounding options were removed.&nbsp;Peptides are short chains of amino acids that play a key role in regulating biological functions. Certain varieties are marketed for potential benefits, such as supporting muscle growth, enhancing immune response, and promoting healthier aging, though their effectiveness can vary by compound and clinical evidence.He said the original decision was framed around regulatory authority but maintained that safety concerns had not changed. According to Kennedy, the review underway could result in formal changes within the next few weeks. Kennedy added that he is personally supportive of peptide therapies, saying he is “a big fan of peptides” and has used them himself for injury recovery.The development comes as policymakers also examine broader therapeutic categories, including psychedelics and other non-traditional treatments, as part of a push to modernize access to certain therapies under tighter guidelines.<h2 class="st-heading-2">Peptide Shift A ‘Gamechanger’ For HIMS</h2>The Futurum Group CEO Daniel Newman&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/danielnewmanUV/status/2028393809340469618">said on X</a> that Hims “is the most likely public company play for peptides at scale” and said the category “could easily offset any GLP-1 related downside.”Jonah Lupton, CEO and CIO of Lupton Capital, called the development a “gamechanger for the company and the stock price,”&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/JonahLupton/status/2028283530933911998">on X</a> and said that moving 14 peptides back to Category-1 would allow U.S.-based compounding pharmacies to produce and sell them without risk of shutdown.Lupton said the shift could bring “transparency, safety and accountability” to a market he expects to surpass $100 billion by 2030. He noted that Hims &amp; Hers acquired a U.S.-based peptide facility in California last year and now serves roughly 2.5 million members.“With 2.5 million members and growing (thanks to recent acquisitions),<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/search?q=%24HIMS&amp;src=cashtag_click"> $HIMS</a> is well positioned to capitalize on the peptide boom that I believe is about to take off around the world,” Lupton said.<h2 class="st-heading-2">CEO: GLP-1 A Small Share Of Subscribers</h2>The renewed focus on peptides comes as Hims &amp; Hers continues to navigate scrutiny around compounded GLP-1 offerings. On its most recent&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-slumps-after-hours-how-ceo-dudum-plans-to-offset-glp-1-risk/cZRviIhR4z3">earnings call</a>, CEO Andrew Dudum said that GLP-1 users who are on a compounded regimen represent only a small minority of the company’s subscriber base. The company pointed to expansion across hormone therapy, lab diagnostics, dermatology, sexual health and menopause care as part of a broader preventive-health strategy.The company reiterated long-term financial targets of at least $6.5 billion in revenue and $1.3 billion in adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) by 2030, while noting that its 2026 outlook assumes continued access to compounded semaglutide.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for HIMS was ‘neutral’ amid ‘low’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_d444f7a0ca.webp" alt="hims ss.png" width="973" height="139"><figcaption>HIMS sentiment and message volume as of March 3 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/RaihanMeazza/message/646391054">said</a>, “We're waiting for the market to cool off. Then, this will have a run!”<stembedurl>https://stocktwits.com/RaihanMeazza/message/646391054</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Pedje/message/646370934">said</a>, “peptides is the future. I lost 20 lbs on two months from taking Glp-3”<stembedurl>https://stocktwits.com/Pedje/message/646370934</stembedurl>HIMS stock has declined nearly 50% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

Hims & Hers Finds A GLP-1 Hedge? HIMS Stock Rallies As RFK Jr. Signals Peptide Clearances

The Futurum Group CEO Daniel Newman said Hims is the “most likely public company play” for peptides at scale.

Hims & Hers Health (NYSE:HIMS) Stock Price Up 10.5% - Should You Buy?

Hims & Hers Health (NYSE:HIMS) Stock Price Up 10.5% - Here's Why...

Top Healthcare Stocks To Watch Now - March 2nd

UnitedHealth Group, Johnson & Johnson, Intuitive Surgical, Medtronic, Novartis, Hims & Hers Health, and McKesson are the seven Healthcare stocks to watch today, according to MarketBeat's stock...

Glancy Prongay Wolke & Rotter LLP Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it is investigating potential claims against the board of directors of Hims & Hers Health, Inc...

Hims & Hers Expands Digital Health and Global Platform Strategy

HIMS expands into labs, cancer screening, menopause and global markets, advancing its digital, subscription-driven healthcare platform and preventive care.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

HIMS
Hims & Hers Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest HIMS News

HIMSHims & Hers Health Inc